A Phase 3 interventional study of Abatacept and Adalimumab in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Active, not recruiting at 75 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 18th largest by enrollment, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 58th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 338 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 17th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2021, is one of 22 in phase 3, and was the 84th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the superiority in efficacy of abatacept compared with adalimumab, on background methotrexate, in adults with early, seropositive, and shared epitope-positive rheumatoid arthritis and an inadequate methotrexate response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept · Drug: Methotrexate
Drug: Abatacept · Drug: Adalimumab · Drug: Methotrexate
Abatacept SC (125 mg) once weekly
Also known as: BMS-188667, Orencia®
Adalimumab SC (40 mg) once every 2 weeks
Also known as: Humira®
Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, week 24
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 24
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.
Time frame: Week 24
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, week 24
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 24
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.
Time frame: Week 24
Adjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24
Participant-reported pain by a 0-100mm visual analog scale; higher score indicates more pain. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, week 24
Percentage of SE+ Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Percentage of SE+ Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.
Time frame: Day 29, 57, 85, 113, 141, 169
Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.
Time frame: Day 29, 57, 85, 113, 141, 169
Percentage of SE+ Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.
Time frame: Day 29, 57, 85, 113, 141, 169
Percentage of Participants Meeting 20% Improvement in American College of Rheumatology Criteria (ACR20) Response Over Time
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response Over Time
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Percentage of Participants Meeting 70% Improvement in American College of Rheumatology Criteria (ACR70) Response Over Time
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Percentage of Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) Over Time
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.
Time frame: Day 29, 57, 85, 113, 141, 169
Percentage of Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) Over Time
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.
Time frame: Day 29, 57, 85, 113, 141, 169
Percentage of Participants Achieving Simple Disease Activity Index Remission (SDAI <= 3.3) Over Time
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.
Time frame: Day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for SE+ Participants
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for SE+ Participants
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for SE+ Participants
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for SE+ Participants
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for SE+ Participants
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for SE+ Participants
6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for SE+ Participants
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein (DAS28-CRP) Over Time for All Participants
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Over Time for All Participants
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in Simple Disease Activity Index (SDAI) Over Time for All Participants
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 3-5 Over Time for All Participants
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 1-2 Over Time for All Participants
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 6 Over Time for All Participants
6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in American College of Rheumatology (ACR) Core Components 7 Over Time for All Participants
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
Time frame: Baseline, day 29, 57, 85, 113, 141, 169
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) Over Time for SE+ Participants
SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.
Time frame: Up to week 24
Adjusted Mean Change From Baseline in SF-36 Over Time for All Participants
SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.
Time frame: Up to week 24
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for SE+ Participants
The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Up to week 24
Adjusted Mean Change From Baseline in 36-item Short Form Survey (SF-36) at Week 104 for All Participants
The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Time frame: Up to week 24
| Milestone | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Started | 169 | 169 |
| Treated in open-label | 160 | 161 |
| Completed | 162 | 162 |
| Not completed | 7 | 7 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Participant request to discontinue study treatment | 1 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Other reasons | 1 | 1 |
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24 | 59.0 (49.5 to 68.0) | 60.3 (50.8 to 69.3) |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Percentage of SE+ Participants Achieving Disease Activity Score 28 Joint Count Calculated Using C Reactive Protein Remission (DAS28-CRP < 2.6) at Week 24 | 44.4 (35.3 to 53.9) | 46.6 (37.2 to 56.0) |
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Percentage of Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24 | 59.2 (51.4 to 66.7) | 63.9 (56.2 to 71.1) |
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Percentage of SE+ Participants Achieving Clinical Disease Activity Index Remission (CDAI <= 2.8) at Week 24 | 33.3 (24.9 to 42.6) | 35.3 (26.7 to 44.8) |
Participant-reported pain by a 0-100mm visual analog scale; higher score indicates more pain. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| Score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Adjusted Mean Change From Baseline in SE+ Participant-Reported Pain Visual Analog Scale (VAS) at Week 24 | -40.9 ± 2.256 | -37.7 ± 2.288 |
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 47.0 (37.7 to 56.5) | 51.7 (42.3 to 61.1) |
| Day 57 | 66.7 (57.4 to 75.1) | 71.6 (62.4 to 79.5) |
| Day 85 | 74.4 (65.5 to 82.0) | 75.9 (67.0 to 83.3) |
| Day 113 | 85.5 (77.8 to 91.3) | 76.7 (68.0 to 84.1) |
| Day 141 | 82.9 (74.8 to 89.2) | 79.3 (70.8 to 86.3) |
| Day 169 | 76.9 (68.2 to 84.2) | 75.9 (67.0 to 83.3) |
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 20.5 (13.6 to 29.0) | 26.7 (18.9 to 35.7) |
| Day 57 | 38.5 (29.6 to 47.9) | 43.1 (33.9 to 52.6) |
| Day 85 | 54.7 (45.2 to 63.9) | 54.3 (44.8 to 63.6) |
| Day 113 | 60.7 (51.2 to 69.6) | 59.5 (50.0 to 68.5) |
| Day 141 | 60.7 (51.2 to 69.6) | 60.3 (50.8 to 69.3) |
| Day 169 | 59.0 (49.5 to 68.0) | 60.3 (50.8 to 69.3) |
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 6.8 (3.0 to 13.0) | 10.3 (5.5 to 17.4) |
| Day 57 | 17.9 (11.5 to 26.1) | 24.1 (16.7 to 33.0) |
| Day 85 | 30.8 (22.6 to 40.0) | 35.3 (26.7 to 44.8) |
| Day 113 | 35.0 (26.5 to 44.4) | 35.3 (26.7 to 44.8) |
| Day 141 | 40.2 (31.2 to 49.6) | 44.0 (34.8 to 53.5) |
| Day 169 | 39.3 (30.4 to 48.8) | 47.4 (38.1 to 56.9) |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 12.8 (7.4 to 20.3) | 16.4 (10.2 to 24.4) |
| Day 57 | 30.8 (22.6 to 40.0) | 32.8 (24.3 to 42.1) |
| Day 85 | 41.0 (32.0 to 50.5) | 40.5 (31.5 to 50.0) |
| Day 113 | 49.6 (40.2 to 59.0) | 52.6 (43.1 to 61.9) |
| Day 141 | 54.7 (45.2 to 63.9) | 52.6 (43.1 to 61.9) |
| Day 169 | 44.4 (35.3 to 53.9) | 46.6 (37.2 to 56.0) |
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 9.4 (4.8 to 16.2) | 6.0 (2.5 to 12.0) |
| Day 57 | 17.1 (10.8 to 25.2) | 13.8 (8.1 to 21.4) |
| Day 85 | 26.5 (18.8 to 35.5) | 19.8 (13.0 to 28.3) |
| Day 113 | 29.1 (21.0 to 38.2) | 32.8 (24.3 to 42.1) |
| Day 141 | 34.2 (25.7 to 43.5) | 30.2 (22.0 to 39.4) |
| Day 169 | 33.3 (24.9 to 42.6) | 35.3 (26.7 to 44.8) |
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 9.4 (4.8 to 16.2) | 7.8 (3.6 to 14.2) |
| Day 57 | 17.1 (10.8 to 25.2) | 14.7 (8.8 to 22.4) |
| Day 85 | 24.8 (17.3 to 33.6) | 19.8 (13.0 to 28.3) |
| Day 113 | 31.6 (23.3 to 40.9) | 31.9 (23.6 to 41.2) |
| Day 141 | 35.9 (27.2 to 45.3) | 32.8 (24.3 to 42.1) |
| Day 169 | 33.3 (24.9 to 42.6) | 34.5 (25.9 to 43.9) |
The ACR 20 definition of improvement is a 20% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 20% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 46.7 (39.0 to 54.6) | 52.1 (44.3 to 59.8) |
| Day 57 | 66.3 (58.6 to 73.4) | 68.6 (61.1 to 75.5) |
| Day 85 | 72.8 (65.4 to 79.3) | 76.3 (69.2 to 82.5) |
| Day 113 | 85.2 (78.9 to 90.2) | 79.9 (73.0 to 85.6) |
| Day 141 | 84.0 (77.6 to 89.2) | 79.9 (73.0 to 85.6) |
| Day 169 | 77.5 (70.5 to 83.6) | 76.9 (69.8 to 83.0) |
The ACR 50 definition of improvement is a 50% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 50% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 20.1 (14.4 to 27.0) | 27.2 (20.7 to 34.6) |
| Day 57 | 38.5 (31.1 to 46.2) | 41.4 (33.9 to 49.2) |
| Day 85 | 52.7 (44.9 to 60.4) | 53.3 (45.4 to 61.0) |
| Day 113 | 60.4 (52.6 to 67.8) | 59.8 (52.0 to 67.2) |
| Day 141 | 61.5 (53.8 to 68.9) | 58.6 (50.8 to 66.1) |
| Day 169 | 59.2 (51.4 to 66.7) | 63.9 (56.2 to 71.1) |
The ACR 70 definition of improvement is a 70% improvement over baseline in tender and swollen joint counts (#1 and #2) and a 70% improvement in 3 of the 5 remaining core data set measures (Participant global assessment of pain, participant global assessment of disease activity, physician global assessment of disease activity, participant assessment of physical function, and acute phase reactant value). Baseline value is the last assessment taken prior to first dose of single-blind study medication.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 5.9 (2.9 to 10.6) | 10.1 (6.0 to 15.6) |
| Day 57 | 20.7 (14.9 to 27.6) | 23.1 (17.0 to 30.2) |
| Day 85 | 30.2 (23.4 to 37.7) | 32.0 (25.0 to 39.6) |
| Day 113 | 35.5 (28.3 to 43.2) | 33.7 (26.6 to 41.4) |
| Day 141 | 40.2 (32.8 to 48.0) | 40.8 (33.3 to 48.6) |
| Day 169 | 39.1 (31.7 to 46.8) | 45.0 (37.3 to 52.8) |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 10.7 (6.4 to 16.3) | 16.6 (11.3 to 23.0) |
| Day 57 | 27.2 (20.7 to 34.6) | 33.7 (26.6 to 41.4) |
| Day 85 | 37.3 (30.0 to 45.0) | 40.8 (33.3 to 48.6) |
| Day 113 | 49.7 (41.9 to 57.5) | 54.4 (46.6 to 62.1) |
| Day 141 | 54.4 (46.6 to 62.1) | 51.5 (43.7 to 59.2) |
| Day 169 | 46.7 (39.0 to 54.6) | 50.9 (43.1 to 58.6) |
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 7.7 (4.2 to 12.8) | 6.5 (3.3 to 11.3) |
| Day 57 | 15.4 (10.3 to 21.7) | 14.2 (9.3 to 20.4) |
| Day 85 | 24.9 (18.5 to 32.1) | 20.7 (14.9 to 27.6) |
| Day 113 | 31.4 (24.5 to 38.9) | 29.0 (22.3 to 36.5) |
| Day 141 | 34.3 (27.2 to 42.0) | 29.0 (22.3 to 36.5) |
| Day 169 | 33.7 (26.6 to 41.4) | 32.5 (25.5 to 40.2) |
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL.
| Percentage of participants | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | 7.7 (4.2 to 12.8) | 7.7 (4.2 to 12.8) |
| Day 57 | 14.8 (9.8 to 21.1) | 16.0 (10.8 to 22.4) |
| Day 85 | 23.1 (17.0 to 30.2) | 20.7 (14.9 to 27.6) |
| Day 113 | 33.1 (26.1 to 40.8) | 28.4 (21.7 to 35.8) |
| Day 141 | 35.5 (28.3 to 43.2) | 28.4 (21.7 to 35.8) |
| Day 169 | 34.3 (27.2 to 42.0) | 31.4 (24.5 to 38.9) |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | -1.3 ± 0.099 | -1.6 ± 0.099 |
| Day 57 | -2.0 ± 0.104 | -2.1 ± 0.109 |
| Day 85 | -2.3 ± 0.109 | -2.4 ± 0.112 |
| Day 113 | -2.7 ± 0.099 | -2.6 ± 0.101 |
| Day 141 | -2.7 ± 0.101 | -2.6 ± 0.102 |
| Day 169 | -2.6 ± 0.114 | -2.6 ± 0.116 |
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | -15.5 ± 0.972 | -15.9 ± 0.955 |
| Day 57 | -21.3 ± 0.928 | -21.9 ± 0.949 |
| Day 85 | -24.6 ± 0.928 | -23.7 ± 0.945 |
| Day 113 | -26.8 ± 0.798 | -25.6 ± 0.808 |
| Day 141 | -27.3 ± 0.783 | -25.6 ± 0.780 |
| Day 169 | -26.9 ± 0.959 | -25.5 ± 0.959 |
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | -15.6 ± 1.008 | -16.7 ± 0.990 |
| Day 57 | -21.9 ± 0.931 | -22.5 ± 0.962 |
| Day 85 | -25.3 ± 0.935 | -24.6 ± 0.953 |
| Day 113 | -27.5 ± 0.797 | -26.3 ± 0.807 |
| Day 141 | -28.1 ± 0.791 | -26.4 ± 0.787 |
| Day 169 | -27.6 ± 0.978 | -26.1 ± 0.983 |
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: Participants Global Assess Disease Activity (mm) | -20.0 ± 2.230 | -21.4 ± 2.230 |
| Day 29: Physician Global Assess Disease Activity (mm) | -26.8 ± 1.896 | -27.1 ± 1.870 |
| Day 29: Participants Assessment of Pain (mm) | -19.5 ± 2.219 | -23.6 ± 2.229 |
| Day 57: Participants Global Assess Disease Activity (mm) | -25.7 ± 2.205 | -28.4 ± 2.276 |
| Day 57: Physician Global Assess Disease Activity (mm) | -37.7 ± 1.782 | -37.6 ± 1.806 |
| Day 57: Participants Assessment of Pain (mm) | -24.8 ± 2.305 | -29.1 ± 2.358 |
| Day 85: Participants Global Assess Disease Activity (mm) | -33.4 ± 2.239 | -32.9 ± 2.302 |
| Day 85: Physician Global Assess Disease Activity (mm) | -43.8 ± 1.660 | -42.2 ± 1.675 |
| Day 85: Participants Assessment of Pain (mm) | -33.1 ± 2.321 | -33.3 ± 2.363 |
| Day 113: Participants Global Assess Disease Activity (mm) | -37.7 ± 2.124 | -35.7 ± 2.162 |
| Day 113: Physician Global Assess Disease Activity (mm) | -47.6 ± 1.462 | -45.8 ± 1.482 |
| Day 113: Participants Assessment of Pain (mm) | -37.0 ± 2.207 | -34.3 ± 2.237 |
| Day 141: Participants Global Assess Disease Activity (mm) | -38.8 ± 2.243 | -35.0 ± 2.274 |
| Day 141: Physician Global Assess Disease Activity (mm) | -48.9 ± 1.498 | -45.7 ± 1.491 |
| Day 141: Participants Assessment of Pain (mm) | -39.0 ± 2.212 | -38.3 ± 2.223 |
| Day 169: Participants Global Assess Disease Activity (mm) | -39.6 ± 2.237 | -36.0 ± 2.278 |
| Day 169: Physician Global Assess Disease Activity (mm) | -48.0 ± 1.683 | -45.9 ± 1.683 |
| Day 169: Participants Assessment of Pain (mm) | -40.9 ± 2.256 | -37.7 ± 2.288 |
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| Joints count | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: Total Tender Joint Count | -9.1 ± 0.580 | -8.6 ± 0.580 |
| Day 29: Total Swollen Joint Count | -6.2 ± 0.422 | -6.7 ± 0.422 |
| Day 57: Total Tender Joint Count | -11.9 ± 0.608 | -11.6 ± 0.621 |
| Day 57: Total Swollen Joint Count | -8.6 ± 0.378 | -8.8 ± 0.386 |
| Day 85: Total Tender Joint Count | -13.5 ± 0.608 | -12.7 ± 0.618 |
| Day 85: Total Swollen Joint Count | -9.5 ± 0.352 | -9.4 ± 0.358 |
| Day 113: Total Tender Joint Count | -14.5 ± 0.516 | -13.8 ± 0.526 |
| Day 113: Total Swollen Joint Count | -10.1 ± 0.321 | -9.8 ± 0.326 |
| Day 141: Total Tender Joint Count | -14.8 ± 0.499 | -13.9 ± 0.506 |
| Day 141: Total Swollen Joint Count | -10.4 ± 0.321 | -9.8 ± 0.325 |
| Day 169: Total Tender Joint Count | -14.7 ± 0.580 | -13.8 ± 0.583 |
| Day 169: Total Swollen Joint Count | -10.2 ± 0.397 | -9.7 ± 0.399 |
6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: Disability Index | -0.4 ± 0.047 | -0.5 ± 0.047 |
| Day 57: Disability Index | -0.6 ± 0.049 | -0.6 ± 0.050 |
| Day 85: Disability Index | -0.8 ± 0.050 | -0.7 ± 0.051 |
| Day 113: Disability Index | -0.8 ± 0.047 | -0.7 ± 0.048 |
| Day 141: Disability Index | -0.9 ± 0.046 | -0.8 ± 0.046 |
| Day 169: Disability Index | -0.9 ± 0.049 | -0.8 ± 0.050 |
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| mg/L | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: C Reactive Protein (mg/L) | -1.4 ± 1.986 | -8.1 ± 1.995 |
| Day 57: C Reactive Protein (mg/L) | -6.1 ± 0.818 | -7.4 ± 0.845 |
| Day 85: C Reactive Protein (mg/L) | -6.7 ± 0.745 | -8.6 ± 0.759 |
| Day 113: C Reactive Protein (mg/L) | -7.5 ± 0.701 | -7.3 ± 0.713 |
| Day 141: C Reactive Protein (mg/L) | -7.9 ± 0.724 | -7.6 ± 0.733 |
| Day 169: C Reactive Protein (mg/L) | -6.6 ± 1.083 | -5.4 ± 1.098 |
DAS28-CRP is a continuous variable which is a composite of 4 variables: the number of tender joints out of a pre-specified 28 joints, the number of swollen joints out of a pre-specified 28 joints, C-reactive protein in mg/L (CRP) and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP scores range from 0 to 10; higher scores indicate more active disease. Remission was defined as DAS28-CRP \< 2.6. DAS28-CRP is calculated using the following formula: DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 where t28 = number of painful joints from 28 joints, sw28 = number of swollen joints from 28 joints, CRP = c-reactive protein in mg/L, and GH = general health or patient's global assessment of disease activity on a 100 mm VAS. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | -1.2 ± 0.084 | -1.5 ± 0.084 |
| Day 57 | -1.9 ± 0.089 | -2.1 ± 0.089 |
| Day 85 | -2.2 ± 0.091 | -2.4 ± 0.091 |
| Day 113 | -2.6 ± 0.084 | -2.6 ± 0.084 |
| Day 141 | -2.7 ± 0.085 | -2.5 ± 0.085 |
| Day 169 | -2.6 ± 0.094 | -2.6 ± 0.093 |
CDAI is a simple linear sum of the following four components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm). CDAI scores range from 2-76; higher scores indicate more active disease. CDAI remission was defined as =\<2.8. CDAI is calculated using the following formula: TJC + SJC + PGA + MDGA where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, and MDGA = physician global assessment on a visual analog scale 0-10 cm. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | -14.6 ± 0.818 | -15.9 ± 0.823 |
| Day 57 | -20.9 ± 0.786 | -21.6 ± 0.784 |
| Day 85 | -23.5 ± 0.763 | -23.5 ± 0.769 |
| Day 113 | -26.6 ± 0.644 | -25.4 ± 0.646 |
| Day 141 | -27.1 ± 0.647 | -25.2 ± 0.631 |
| Day 169 | -26.7 ± 0.763 | -25.4 ± 0.749 |
SDAI is a simple linear sum of the following five components: Tender joint counts out of 28 joints, Swollen joint counts out of 28 joints, Participant global assessment of disease activity (0-10cm), Physicians global assessment of disease activity (0-10cm), high-sensitivity C-reactive protein (hsCRP mg/dL). SDAI total scores range from 0-86; higher scores indicate more active disease. Remission was defined as SDAI =\< 3.3. SDAI is calculated using the following formula: TJC + SJC + PGA + MDGA + CRP where TJC = number of painful joints from 28 joints, SJC = number of swollen joints from 28 joints, PGA = patient global assessment on a visual analog scale 0-10 cm, MDGA = physician global assessment on a visual analog scale 0-10 cm, and CRP = c-reactive protein in mg/dL. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
| Score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29 | -14.7 ± 0.843 | -16.6 ± 0.849 |
| Day 57 | -21.5 ± 0.788 | -22.1 ± 0.789 |
| Day 85 | -24.0 ± 0.769 | -24.2 ± 0.775 |
| Day 113 | -27.2 ± 0.648 | -26.0 ± 0.649 |
| Day 141 | -27.7 ± 0.661 | -25.8 ± 0.647 |
| Day 169 | -27.3 ± 0.787 | -26.0 ± 0.771 |
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: Participants Global Assess Disease Activity (mm) | -19.4 ± 1.865 | -20.6 ± 1.868 |
| Day 29: Physician Global Assess Disease Activity (mm) | -24.4 ± 1.613 | -27.7 ± 1.612 |
| Day 29: Participants Assessment of Pain (mm) | -19.2 ± 1.872 | -22.7 ± 1.863 |
| Day 57: Participants Global Assess Disease Activity (mm) | -27.3 ± 1.888 | -28.3 ± 1.893 |
| Day 57: Physician Global Assess Disease Activity (mm) | -35.7 ± 1.583 | -36.7 ± 1.579 |
| Day 57: Participants Assessment of Pain (mm) | -25.9 ± 1.957 | -28.7 ± 1.954 |
| Day 85: Participants Global Assess Disease Activity (mm) | -32.8 ± 1.874 | -32.8 ± 1.884 |
| Day 85: Physician Global Assess Disease Activity (mm) | -40.1 ± 1.459 | -41.2 ± 1.459 |
| Day 85: Participants Assessment of Pain (mm) | -32.1 ± 1.939 | -33.7 ± 1.923 |
| Day 113: Participants Global Assess Disease Activity (mm) | -37.7 ± 1.787 | -34.8 ± 1.780 |
| Day 113: Physician Global Assess Disease Activity (mm) | -46.8 ± 1.216 | -44.9 ± 1.218 |
| Day 113: Participants Assessment of Pain (mm) | -36.6 ± 1.883 | -33.9 ± 1.871 |
| Day 141: Participants Global Assess Disease Activity (mm) | -38.4 ± 1.866 | -34.1 ± 1.856 |
| Day 141: Physician Global Assess Disease Activity (mm) | -48.5 ± 1.258 | -45.2 ± 1.221 |
| Day 141: Participants Assessment of Pain (mm) | -38.7 ± 1.858 | -35.4 ± 1.830 |
| Day 169: Participants Global Assess Disease Activity (mm) | -39.1 ± 1.842 | -36.6 ± 1.827 |
| Day 169: Physician Global Assess Disease Activity (mm) | -47.7 ± 1.320 | -46.2 ± 1.296 |
| Day 169: Participants Assessment of Pain (mm) | -39.5 ± 1.895 | -37.0 ± 1.864 |
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| Joints count | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: Total Tender Joint Count | -8.1 ± 0.529 | -8.2 ± 0.527 |
| Day 29: Total Swollen Joint Count | -6.1 ± 0.374 | -6.6 ± 0.372 |
| Day 57: Total Tender Joint Count | -11.3 ± 0.549 | -11.1 ± 0.545 |
| Day 57: Total Swollen Joint Count | -8.7 ± 0.322 | -8.7 ± 0.319 |
| Day 85: Total Tender Joint Count | -12.7 ± 0.507 | -12.4 ± 0.506 |
| Day 85: Total Swollen Joint Count | -9.3 ± 0.289 | -9.4 ± 0.289 |
| Day 113: Total Tender Joint Count | -14.4 ± 0.411 | -13.9 ± 0.410 |
| Day 113: Total Swollen Joint Count | -10.1 ± 0.255 | -9.8 ± 0.254 |
| Day 141: Total Tender Joint Count | -14.8 ± 0.417 | -13.8 ± 0.414 |
| Day 141: Total Swollen Joint Count | -10.6 ± 0.259 | -9.9 ± 0.257 |
| Day 169: Total Tender Joint Count | -14.5 ± 0.474 | -13.8 ± 0.468 |
| Day 169: Total Swollen Joint Count | -10.2 ± 0.311 | -9.8 ± 0.307 |
6) Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI). For the eight disability categories (Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities), there is an aids or devices variables to record the type of assistance. If aids or devices and/or assistance from another person are checked for a category, the score is set to 2 (much difficulty), if the original score is 0 (no difficulty) or 1 (some difficulty). HAQ-DI is then calculated by summing the adjusted categories scores and dividing by the number of categories answered (increasing scores for the 8 disability categories questionnaire indicate increasing level of difficulty with 0 being the lowest score "without any difficulty" and 3 being the highest score "unable to do". Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| score on a scale | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: Disability Index | -0.4 ± 0.040 | -0.5 ± 0.040 |
| Day 57: Disability Index | -0.6 ± 0.042 | -0.6 ± 0.042 |
| Day 85: Disability Index | -0.7 ± 0.043 | -0.6 ± 0.043 |
| Day 113: Disability Index | -0.7 ± 0.041 | -0.7 ± 0.041 |
| Day 141: Disability Index | -0.8 ± 0.040 | -0.7 ± 0.040 |
| Day 169: Disability Index | -0.8 ± 0.042 | -0.8 ± 0.042 |
1. Tender joint count (standard 68 joint count) 2. Swollen joint count (standard 66 joint count) 3. Participant global assessment of pain (a 0-100mm visual analog scale with 100 mm being the worst pain) 4. Participant global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the highest disease activity) 5. Physician global assessment of disease activity (a 0-100mm visual analog scale with 100 mm being the worst case) 6. Participant assessment of physical function Health Assessment Questionnaire Disability Index (HAQ-DI) (increasing scores for the 8 disability categories indicate increasing level of difficulty). HAQDI is calculated by summing the adjusted categories scores and dividing by the number of categories answered 7. C-reactive protein (increasing levels indicate increasing level of disease) Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline=Post-baseline - Baseline value.
| mg/L | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 29: C Reactive Protein (mg/L) | -1.4 ± 1.520 | -6.8 ± 1.514 |
| Day 57: C Reactive Protein (mg/L) | -5.7 ± 0.635 | -6.4 ± 0.635 |
| Day 85: C Reactive Protein (mg/L) | -5.4 ± 0.719 | -6.6 ± 0.717 |
| Day 113: C Reactive Protein (mg/L) | -5.7 ± 0.704 | -5.8 ± 0.702 |
| Day 141: C Reactive Protein (mg/L) | -5.9 ± 0.778 | -5.5 ± 0.774 |
| Day 169: C Reactive Protein (mg/L) | -6.2 ± 0.912 | -5.0 ± 0.900 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.
| T-score | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 169: Physical Functioning | 9.2 ± 0.813 | 9.8 ± 0.817 |
| Day 169: Role-Physical | 9.1 ± 0.809 | 8.9 ± 0.805 |
| Day 169: Bodily Pain | 14.2 ± 0.863 | 12.0 ± 0.859 |
| Day 169: General Health | 8.1 ± 0.779 | 6.5 ± 0.783 |
| Day 169: Vitality | 10.0 ± 0.878 | 8.4 ± 0.874 |
| Day 169: Social Functioning | 9.6 ± 0.828 | 9.4 ± 0.824 |
| Day 169: Role-Emotional | 9.0 ± 0.921 | 9.1 ± 0.917 |
| Day 169: Mental Health | 8.9 ± 0.799 | 7.1 ± 0.795 |
| Day 169: Physical Component Summary | 10.2 ± 0.738 | 9.6 ± 0.735 |
| Day 169: Mental Component Summary | 8.4 ± 0.818 | 7.3 ± 0.814 |
SF-36 is a generic 36-item questionnaire measuring health-related quality of life, which covers 8 health dimensions within 2 components. The physical component summary (PCS) consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100, with a higher score indicating better quality of life. The 8 subscales will be scored using norm-based methods that have standardized the T-scores to a mean of 50 and a standard deviation of 10 in the general population.
| T-score | Abatacept | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Day 169: Physical Functioning | 8.9 ± 0.706 | 9.4 ± 0.697 |
| Day 169: Role-Physical | 8.6 ± 0.681 | 8.7 ± 0.669 |
| Day 169: Bodily Pain | 13.5 ± 0.719 | 11.7 ± 0.706 |
| Day 169: General Health | 7.9 ± 0.652 | 6.7 ± 0.644 |
| Day 169: Vitality | 9.4 ± 0.740 | 8.8 ± 0.725 |
| Day 169: Social Functioning | 8.9 ± 0.701 | 9.8 ± 0.690 |
| Day 169: Role-Emotional | 8.4 ± 0.773 | 8.8 ± 0.759 |
| Day 169: Mental Health | 8.0 ± 0.712 | 7.6 ± 0.700 |
| Day 169: Physical Component Summary | 9.9 ± 0.619 | 9.2 ± 0.608 |
| Day 169: Mental Component Summary | 7.6 ± 0.718 | 7.7 ± 0.705 |
The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Results for this outcome have not been posted.
The SF-36 v2.0, which covers 8 health dimensions within 2 components. The physical component summary (PCS) of the SF-36 consists of these 4 subscales: Physical functioning, Role-physical, Bodily pain, General health. The mental component summary (MCS) of the SF-36 consists of these 4 subscales: Vitality, Social functioning, Role-emotional, Mental health. The scores range from 0 to 100, with a higher score indicating better quality of life. The 2 summary scores (PCS and MCS) will be calculated by taking a weighted linear combination of the 8 individual subscales. Baseline value is the last assessment taken prior to first dose of single-blind study medication. Change from Baseline = Post-baseline - Baseline value.
Results for this outcome have not been posted.
Collected over All-cause mortality was collected from first dose till death (Up to 20 months). Serious adverse events and non-serious adverse events were collected from first dose until 56 days after last dose of study therapy (Up to approximately 9 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept Only | 0/169 (0%) | 4/169 (2.4%) | 34/169 (20.1%) |
| Adalimumab, Then Abatacept (OLE Period) | 0/169 (0%) | 6/169 (3.6%) | 41/169 (24.3%) |
| Event | Abatacept Only | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| Atypical pneumoniaInfections and infestations | 0/169 | 1/169 |
| Pilonidal diseaseInfections and infestations | 0/169 | 1/169 |
| Open fractureInjury, poisoning and procedural complications | 1/169 | 0/169 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/169 | 1/169 |
| Foot deformityMusculoskeletal and connective tissue disorders | 1/169 | 0/169 |
| Neuroendocrine tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/169 | 0/169 |
| Migraine with auraNervous system disorders | 0/169 | 1/169 |
| Renal colicRenal and urinary disorders | 1/169 | 0/169 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/169 | 1/169 |
| HaematomaVascular disorders | 0/169 | 1/169 |
| Event | Abatacept Only | Adalimumab, Then Abatacept (OLE Period) |
|---|---|---|
| COVID-19Infections and infestations | 20/169 | 23/169 |
| NasopharyngitisInfections and infestations | 11/169 | 10/169 |
| Upper respiratory tract infectionInfections and infestations | 4/169 | 10/169 |
| Age, Continuous(Years) | Abatacept | Adalimumab, Then Abatacept (OLE Period) | Total |
|---|---|---|---|
| Mean | 49.3 ± 13.71 | 47.4 ± 13.43 | 48.4 ± 13.59 |
| Sex: Female, Male(Participants) | Abatacept | Adalimumab, Then Abatacept (OLE Period) | Total |
|---|---|---|---|
| Female | 130 | 138 | 268 |
| Male | 39 | 31 | 70 |
| Race (NIH/OMB)(Participants) | Abatacept | Adalimumab, Then Abatacept (OLE Period) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 9 | 18 |
| Asian | 17 | 23 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 5 |
| White | 122 | 113 | 235 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 17 | 23 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Jun 2023, 20 months.
Results were first posted in Oct 2024, 1 year 4 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 20 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abatacept · Methotrexate